Related Experiment Videos
Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit?
A Böhme1, M Karthaus, D Hoelzer
1Medical Clinic III, Hematology/Oncology, J.W. Goethe University, Frankfurt, Germany.
Abstract:
Invasive fungal infections have been reported with an increasing incidence over the last 20 years. Fungal infections are an important cause of morbidity and mortality in patients with hematological malignancies. Therefore, in neutropenic patients different regimens of antifungal prophylaxis have been performed for more than 20 years, but the effect of antifungal prophylaxis is controversial. A long duration of neutropenia, impaired cell-mediated immunity as well as continuous corticosteroid therapy and sustained immunosuppression for graft-versus-host disease in patients treated with allogeneic bone marrow transplantation are known risk factors for invasive mycosis. Since early diagnosis of invasive fungal infection is difficult, strategies to prevent fungal infections seem to be attractive. The introduction of triazoles have provided us with a better armamentarium to prevent fungal infections. In this review, the current strategies of antifungal prophylaxis are discussed. Antifungal prophylaxis has been effective in reducing candida infection, however, there has been no proven successful prevention of invasive aspergillosis. In addition, there is no clearly proven benefit of antifungal prophylaxis regarding the reduction in the overall mortality. Thus the best way to reduce invasive fungal-related mortality will be early diagnosis and preemptive therapeutic approaches.
Insights
Antifungal prophylaxis in neutropenic patients shows mixed results, effectively reducing Candida infections but not invasive aspergillosis. Early diagnosis and preemptive treatment are key to lowering fungal infection mortality.
Area of Science:
- Mycology
- Hematology
- Infectious Diseases
Background:
- Invasive fungal infections (IFIs) incidence is rising, posing significant risks for patients with hematological malignancies.
- Neutropenic patients, especially those undergoing allogeneic bone marrow transplantation, face increased risk due to factors like prolonged neutropenia and immunosuppression.
- Current antifungal prophylaxis strategies have been employed for over two decades with controversial efficacy.
Purpose of the Study:
- To review current strategies for antifungal prophylaxis in neutropenic patients.
- To evaluate the effectiveness of antifungal prophylaxis in preventing invasive fungal infections and reducing mortality.
- To discuss the role of early diagnosis and preemptive treatment in managing IFIs.
Main Methods:
- This is a review article, synthesizing existing literature on antifungal prophylaxis.
- The review discusses various antifungal regimens, particularly triazoles, used in neutropenic patients.
- Risk factors for invasive mycosis in this patient population are identified and analyzed.
Main Results:
- Antifungal prophylaxis has demonstrated efficacy in reducing Candida infections.
- However, proven success in preventing invasive aspergillosis through prophylaxis remains elusive.
- No clear benefit of antifungal prophylaxis in reducing overall mortality has been established.
Conclusions:
- While effective against Candida, antifungal prophylaxis has limitations in preventing aspergillosis.
- Early diagnosis and preemptive therapeutic approaches are crucial for reducing invasive fungal-related mortality.
- Optimizing IFI management requires a shift towards timely detection and intervention.